SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is driving intense market conversation due to a historic short squeeze fueled by highly concentrated ownership among two major hedge funds, which effectively control the majority of the float and have limited available shares for short covering. Community members are actively debating the sustainability of this parabolic move, with many highlighting extreme technical indicators, high volatility, and potential regulatory scrutiny, while retail traders remain split between chasing the momentum and betting on an inevitable correction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to a pivotal executive interview confirming production orders and scaling manufacturing for AI hyperscaler demand. The community is actively dismissing recent short-seller reports and debating the company's transition from speculative tech to a commercial revenue story, while speculating on the impact of potential index inclusion and strategic partnerships.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing strong momentum as institutional interest shifts toward a catch-up trade, supported by bullish analyst price target hikes and major hyperscaler commitments from Meta and OpenAI. The community remains highly active, debating the stock's potential for sustained growth against its current valuation and the ongoing battle between hardware and software-driven AI returns.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing extreme volatility and rapid gains, fueled by persistent AI-driven optimism, ongoing semiconductor strength, and a market environment that continues to defy bearish expectations. While some traders are riding the aggressive momentum to new highs, a vocal segment of the community remains cautious, citing concerns over potential overextension, the structural risks of leveraged ETFs in choppy conditions, and uncertainty regarding geopolitical tensions.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following a strategic investment in French rare-earth specialist Carester, which creates a vital midstream processing path for its Texas-based feedstock. The community is actively debating the stock's valuation, weighing its long-term potential for domestic supply chain independence against concerns regarding share dilution and the volatility of its pre-production status.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is trending as investors react to positive topline results from its registrational phase two trial of miv-cel for stiff person syndrome, which showed significant clinical benefits and a clean safety profile. The community is actively discussing the potential for a near-term buyout or partnership, fueled by the company's best-in-class CAR-T pipeline, experienced management, and its path toward a biologics license application.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

The community surrounding $IMG is rallying behind the token's passive Solana rewards and deflationary mechanisms, framing it as a 'battle-tested' utility play that has survived significant market adversity. Investors are actively discussing the protocol's technological resilience and upcoming milestones, viewing current entry levels as a strategic opportunity to accumulate ahead of a potential supply shock.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant momentum driven by investor enthusiasm for its gallium nitride power technology, which is increasingly viewed as a critical component for AI data center efficiency. While bulls point to high-profile industry partnerships and long-term demand for AI infrastructure, the stock remains a flashpoint for debate, as skeptics warn that current price action is fueled by sentiment and short-term speculative positioning rather than immediate earnings-based fundamentals.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is currently generating significant community buzz, driven by optimistic analyst revisions and anticipation for profitability by 2026 as its GI-focused commercial strategy gains traction. Investors are actively discussing the company as a prime acquisition target for Big Pharma, fueled by a combination of high prescription growth, recent patent exclusivity protections, and a tightening expense profile that signals strong long-term value creation.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is gaining significant momentum as investors digest recent positive clinical data, a strengthened balance sheet following an upsized financing, and its status as the only CAR-T therapy with Breakthrough Therapy Designation for AL Amyloidosis. The community is actively tracking the upcoming completion of trial enrollment and the potential for new institutional analyst coverage, viewing the stock as a de-risked platform play with significant long-term upside potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


E6_F
EUR/USD Futures

Feed

News

Sentiment

Contract Specs

Latest E6_F News

E6_FEUR/USD Futures